Humoral Immune Response After Intravitreal But Not After Subretinal AAV8 in Primates and Patients
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Purpose: To study longitudinal changes of anti-drug antibody (ADA) titers to recombinant adeno-associated virus serotype 8 (rAAV8) capsid epitopes in nonhuman primates (NHP) and patients. Methods: Three groups of six NHP each received subretinal injections (high dose: 1 × 1012 vector genomes [vg], low dose: 1 × 1011 vg, or vehicle only). Four additional animals received intravitreal injections of the high dose (1 × 1012 vg). Three patients received 1 × 1010 vg as subretinal injections. ELISA quantified ADA levels at baseline and 1, 2, 3, 7, 28, and 90 days after surgery in NHP and at baseline and 1, 3, and 6 months after surgery in patients. Results: Two out of 22 animals lacked ADA titers at baseline and developed low ADA titers toward the end of the study. Titers in the low-dose group stayed constant, while two of six animals from the high-dose group developed titers that rose beyond the range of the assay. All animals from the intravitreal control group showed a rise in ADA titer by day 7 that peaked at day 28. Preliminary data from the clinical trial (NCT02610582) show no humoral immune response in patients following subretinal delivery of 1 × 1010 vg. Conclusions: No significant induction of ADA occurred in NHP when mimicking the clinical scenario of subretinal delivery with a clinical-grade rAAV8 and concomitant immunosuppression. Likewise, clinical data showed no humoral immune response in patients. In contrast, intravitreal delivery was associated with a substantial humoral immune response. Subretinal delivery might be superior to an intravitreal application regarding immunologic aspects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Intravitreal delivery of adeno-associated virus (AAV) vectors offers a promising, minimally invasive strategy for retinal gene therapy, but remains limited by dose-dependent intraocular inflammation.”
From Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses (2026) · cites this paper as [11]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many studies have shown minimal to absent humoral response to antigens delivered to this space.13,74,75”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other studies also found that gene transduction was achievable if injected in the subretinal space even if the subjects have neutralizing antibodies.74,92”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As expected from previous reports (11), most animals developed anti-AAV2.7m8 IgG antibodies, which were detectable in both VH and AH samples independent of the uveitis scores (Figure 1E).”
From Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses (2026) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the presence of pre-existing neutralizing antibodies to AAV does not appear to correlate with a higher risk of retinal inflammation or reduced therapeutic efficacy, provided that the AAV vector is delivered via the subretinal route.27, 28, 29”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [28]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 2×
“As such, clinical trials in hemophilia patients have shown that circulating antibodies can effectively inhibit transduction even at low titers, and that AAV-directed CD8þ cells target and remove successfully transduced hepatocytes as virus-infected cells.(5) In contrast to the treatment for hemophilia, where AAV vecto…”
BackgroundMethodSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 1×
“It may, however, become relevant in a scenario of multiple injections and/or intravitreal applications.(3,18) Intravitreal may be considered the preferred route of administration when targeting inner layers or wide areas of the retina.”
BackgroundHauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954 · cited 1×
“One study reported a single case in which anti-capsid antibodies emerged in a functional assay around day 14 but declined later,(6) and in another study some anti-capsid antibody titers increased toward day 90 but were still low compared to the overall mean.(8) Amado et al.”
ResultWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395 · cited 1×
“This is in line with the observation that readministration of subretinal AAV (to the contralateral eye) in three adult patients did not lead to a rise in antibody titer.(11) Importantly, though, intravitreal delivery of AAV2 has been shown to induce humoral immune response in mice and block transduction in subsequent…”
ResultImprovement and Decline in Vision with Gene Therapy in Childhood Blindness
Jacobson, S. G., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Schwartz, S. B., Heon, E., & Hauswirth, W. W. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412965 · Cited by 372
Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345 · cited 1×
“Through contact with wild-type AAV, humans develop antibodies against the different serotypes in their first years of life.(15,16) Depending on the study, seroprevalence for AAV8 ranges from 15% to 30% of the population (AAV2: 30%– 60%)(16,17) to 82% in Asian adult humans (AAV2: 97%).”
Background
Research works printed but not linked: 1
- [17]17. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adenoassociated viruses. J Infect Dis . 2009;199:381-390.
Cited by
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Self-citationClinical Perspective: Treating RPE65-Associated Retinal Dystrophy
Maguire, A. M., Bennett, J., Aleman, E. M., Leroy, B. P., & Aleman, T. S. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.029 · Cited by 184
Yiu, G., Chung, S. H., Mollhoff, I. N., Nguyen, U. T., Thomasy, S. M., Yoo, J., Taraborelli, D., & Noronha, G. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.002 · Cited by 153
Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders
Pavlou, M., Schön, C., Occelli, L. M., Rossi, A., Meumann, N., Boyd, R. F., Bartoe, J. T., Siedlecki, J., Gerhardt, M. J., Babutzka, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013392 · Cited by 135
“With regard to the eye, only a transient immune response to intraocular vector delivery has been observed so far, which did not limit treatment success (Reichel et al, 2018; Rabinowitz et al, 2019).”
BackgroundSelf-citationImmunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
Metadata
- Authors
- Reichel, F. F., Peters, T., Wilhelm, B., Biel, M., Ueffing, M., Wissinger, B., Bartz-Schmidt, K. U., Klein, R., Michalakis, S., Fischer, M. D., & for the RD-CURE Consortium
- Affiliations
- University of Tübingen (DE)
- STZ eyetrial (DE)
- Center for Integrated Protein Science Munich (DE)
- University Eye Hospital, University of Tübingen, Tübingen, Germany
- Universitätsklinikum Tübingen (DE)
- University of Oxford (GB)
- Corresponding author
- Fischer, M. Dominik
- ORCID
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2018-04-05
- Volume
- 59
- Issue
- 5
- Pages
- 1910
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2795742690
- Cited by
- 86
- References
- 21
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 11 · 2023: 11 · 2022: 8 · 2021: 19 · 2020: 12 · 2019: 8 · 2018: 1
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- anti-drug antibodies, AAV8, subretinal gene therapy, intravitreal gene therapy, humoral immune response, non-human primates, immunosuppression, vector dose, retinal gene therapy
- MeSH terms
- Dependovirus, Animals, Antibodies, Viral, Color Vision Defects, Enzyme-Linked Immunosorbent Assay, Female, Genetic Vectors, Humans, Macaca fascicularis, Male, Retina, Vitreous Body, Genetic Therapy, Capsid Proteins, Cyclic Nucleotide-Gated Cation Channels, Immunity, Humoral, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.